The estimated Net Worth of Andrew R. Boll is at least $24.6 Milión dollars as of 20 February 2024. Mr. Boll owns over 63,480 units of Harrow Health stock worth over $23,501,842 and over the last 9 years he sold HROW stock worth over $0. In addition, he makes $1,049,220 as Chief Financial Officer a Corporate Secretary at Harrow Health.
Andrew has made over 12 trades of the Harrow Health stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 63,480 units of HROW stock worth $677,332 on 20 February 2024.
The largest trade he's ever made was exercising 346,500 units of Harrow Health stock on 18 July 2023 worth over $14,334,705. On average, Andrew trades about 41,219 units every 147 days since 2016. As of 20 February 2024 he still owns at least 568,089 units of Harrow Health stock.
You can see the complete history of Mr. Boll stock trades at the bottom of the page.
Andrew R. Boll is Chief Financial Officer, Corporate Secretary of the company. Mr. Boll started with Harrow in December 2011, and has served as our Chief Financial Officer since his promotion to that role in February 2015. He oversees the Company’s financial and administrative operations. In addition, Mr. Boll helped form and start-up our subsidiaries Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, Radley Pharmaceuticals, Stowe Pharmaceuticals, and ImprimisRx. Prior to Harrow, from 2007 to 2011, Mr. Boll worked for an investment company and its series of funds where he oversaw the fund’s accounting, financial analysis, and reporting; he was also heavily involved with the financial operations of a number of the fund’s portfolio companies (public and private). Prior to 2007, Mr. Boll held various accounting roles at Welsh Companies, LLC, a commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA® charterholder, Certified Management Accountant and earned his Bachelor of Science degree, summa cum laude, in Corporate and Public Finance at Huron University.
As the Chief Financial Officer a Corporate Secretary of Harrow Health, the total compensation of Andrew Boll at Harrow Health is $1,049,220. There are 1 executives at Harrow Health getting paid more, with Mark Baum having the highest compensation of $1,377,010.
Andrew Boll is 37, he's been the Chief Financial Officer a Corporate Secretary of Harrow Health since 2015. There are 11 older and no younger executives at Harrow Health. The oldest executive at Harrow Health, Inc. is Dr. Robert J. Kammer D.D.S., 72, who is the Special Advisor.
Andrew's mailing address filed with the SEC is 12264 El Camino Real #350, San Diego, CA 92130, USA.
Over the last 6 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock and bought 1,487,560 units worth $12,882,479 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum a Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of $3,323,914. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth $199,400.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Harrow Health executives and other stock owners filed with the SEC include: